⌕
Bayer Aktiengesellschaft · BAYRY · —
Tenet — · insufficient data
Compare
$15.03−2.08%At close
$15.03−0.32 (−2.08%)
At close: Nov 19, 2026, 4:00 PM ET· USD

Bayer Aktiengesellschaft (BAYRY) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

● Zacks Investment ResearchNov 10, 2026 · 15:41 ET
Bayer Wins FDA Approval for Sunharbo for Secondary Stroke Risk Reduction

Bayer gains FDA approval for Sunharbo, the first Factor XIa inhibitor approved worldwide, opening new growth opportunities in stroke prevention.…

● Business WireNov 9, 2026 · 20:11 ET
Bayer's SUNHARBO® (asundexian), 50 mg tablets, the First and Only Factor XIa Inhibitor, Approved by the U.S.

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Bayer's SUNHARBO® (asundexian), 50 mg tablets, the First and Only Factor XIa Inhibitor, Approved by the U.S. FDA to Reduce the Risk of Stroke in Adults With Recent Non-Cardioembolic…

● Zacks Investment ResearchNov 9, 2026 · 09:45 ET
3 Large-Cap Stocks to Watch as Drug & Biotech Sector Rebounds in 2026

In the Large-Cap Pharmaceuticals industry, LLY, NVS and BAYRY are worth watching as the industry shows a strong recovery.…

● Zacks Investment ResearchNov 5, 2026 · 12:41 ET
BAYRY vs. JNJ: Which Stock Is the Better Value Option?

Investors interested in stocks from the Large Cap Pharmaceuticals sector have probably already heard of Bayer Aktiengesellschaft (BAYRY) and Johnson & Johnson (JNJ). But which of these two stocks is more attractive to va…

● Zacks Investment ResearchNov 5, 2026 · 10:41 ET
Are Medical Stocks Lagging Bayer (BAYRY) This Year?

Here is how Bayer Aktiengesellschaft (BAYRY) and Encompass Health (EHC) have performed compared to their sector so far this year.…

● Business WireNov 4, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Bayer and America's Grow-a-Row Continue Partnership to Fight Food Insecurity

PITTSTOWN, N.J.--(BUSINESS WIRE)-- #TeamBAYER--In 2026, Bayer and America's Grow-a-Row continued their longstanding partnership to combat food insecurity and expand access to fresh, nutritious produce for communities acr…

● ReutersNov 4, 2026 · 06:04 ET
Bayer seeks bigger role in fast-growing Latin American biologicals market

Bayer seeks bigger role in fast-growing Latin American biologicals market…

● Zacks Investment ResearchNov 3, 2026 · 15:15 ET
BAYRY Q3 Earnings and Revenues Miss Estimates, Pharma Performs Well

Bayer's Q3 earnings and revenues miss estimates, but strong growth in Nubeqa and Kerendia boosts pharma performance and lifts 2026 EBITDA guidance.…

● Business WireNov 3, 2026 · 14:30 ETCOMPANY'S OWN WORDS
Bayer to Present New Cardiovascular, Kidney and Stroke Data at the 2026 American Heart Association (AHA) Scientific Sessions

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Summary Bayer today announced that new data from its cardiovascular, kidney and stroke portfolios will be featured at the American Heart Association Scientific Sessions in Chicago, …

● Seeking AlphaNov 3, 2026 · 13:54 ET
Bayer AG: Solid Q3 Earnings, But Still A 'Prove-It' Story

Bayer A.G. maintains a 'Hold' rating after a robust Q3, with Pharma outperforming expectations and driving operating leverage. Q3 Pharma EBITDA before special items rose 23.6% to 1.292 billion euro, with margins improvin…

● Seeking AlphaNov 3, 2026 · 11:26 ET
Bayer Aktiengesellschaft (BAYRY) Q3 2026 Earnings Call Transcript

Bayer Aktiengesellschaft (BAYRY) Q3 2026 Earnings Call Transcript…

● MarketBeatNov 3, 2026 · 08:13 ET
What Bayer Aktiengesellschaft (BAYN) Said on Its Q3 Earnings Call

Bayer Aktiengesellschaft ETR: BAYN said it is on track to meet its 2026 commitments after reporting 3% organic sales growth and 7% adjusted EBITDA growth for the first nine months of the year, supported by Pharmaceutical…

● WSJNov 3, 2026 · 02:10 ET
Bayer Raises Earnings Outlook on Pharma Recovery

The German group posted a recovery in its pharma arm after strong demand for key drugs allowed it to offset market pressures at its agricultural and consumer-health divisions.…

● ReutersNov 3, 2026 · 01:43 ET
Bayer raises 2026 profit outlook

Bayer raises 2026 profit outlook…

● WSJOct 26, 2026 · 04:57 ET
Bayer Gets in China Its First Global Approval for Stroke Prevention Drug

The decision hands Bayer the first ever approval for a Factor XIa inhibitor, which aim to slow the activity of a protein that regulates how the body forms clots without increasing the risk of bleeding.…

● Seeking AlphaOct 19, 2026 · 00:51 ET
Bayer: Turnaround Is Gaining Momentum, But Debt Remains A Risk

Bayer (OTCPK:BAYZF) remains a long-term Buy, with the stock still undervalued despite ongoing litigation and high debt levels. Litigation risks are easing, with a major Supreme Court win and a key settlement decision exp…

● Business WireOct 8, 2026 · 15:00 ETCOMPANY'S OWN WORDS
Bayer to Present New Cardiac Amyloidosis and Heart Failure Data at the Heart Failure Society of America (HFSA) Annual Scientific Meeting

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Summary Bayer today announced that one late-breaking presentation along with five posters across its cardiovascular programs will be featured at the Heart Failure Society of America…

● Zacks Investment ResearchOct 8, 2026 · 13:26 ET
Bayer Seeks Kerendia Label Expansion in Non-Diabetic CKD

BAYRY's Kerendia label expansion moves forward as FDA accepts an application for CKD patients without diabetes.…

● Business WireOct 8, 2026 · 08:30 ET
Actress and Menopause Advocate Melissa Joan Hart Partners with Bayer to Raise Awareness about Lynkuet® (elinzanetant), a Prescription Treatment for Moderate to Severe Hot Flashes due to Menopause

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced a partnership with actress and menopause advocate Melissa Joan Hart to increase awareness about Lynkuet® (elinzanetant) 60mg capsules, Bayer's FDA-approved, hormone-…

● Business WireOct 8, 2026 · 02:30 ET
U.S. FDA Accepts Bayer's Supplemental New Drug Application for KERENDIA® (finerenone) to Treat Adults with Chronic Kidney Disease (CKD) Without Diabetes

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Summary Bayer announced today that the U.S. Food and Drug Administration (FDA) accepted the company's supplemental New Drug Application (sNDA) for KERENDIA® (finerenone), which is b…

● Zacks Investment ResearchOct 7, 2026 · 12:41 ET
BAYRY vs. RHHBY: Which Stock Should Value Investors Buy Now?

Investors looking for stocks in the Large Cap Pharmaceuticals sector might want to consider either Bayer Aktiengesellschaft (BAYRY) or Roche Holding AG (RHHBY). But which of these two companies is the best option for tho…

● WSJOct 2, 2026 · 15:27 ET
Bayer to Invest $2.2 Billion in U.S. Pharma Manufacturing Expansion

The German company, which said its new site in Ohio will create around 600 jobs, is the latest European drugmaker to invest in the U.S.…

● ReutersOct 2, 2026 · 15:17 ET
Bayer to invest $2.2 billion in new US pharma site

Bayer's pharmaceuticals unit on Friday unveiled plans to invest $2.2 billion in a new manufacturing ​site in New Albany, Ohio, part of a ‌push to boost the business's US revenue.…

● Business WireOct 2, 2026 · 15:10 ETCOMPANY'S OWN WORDS
Bayer to Invest 2.2 Billion U.S. Dollars in a New Manufacturing Site in the United States

NEW ALBANY, Ohio--(BUSINESS WIRE)--Bayer announced on Friday plans to invest 2.2 billion U.S. dollars in a new pharmaceutical manufacturing site in New Albany, Ohio, U.S. Building on more than seven billion dollars in U.…

● ReutersSep 29, 2026 · 17:42 ET
Bayer faces trial test of remaining Roundup claims after US Supreme Court win

Attorneys for ​three cancer patients told a Missouri jury on Tuesday that Bayer's Monsanto unit failed to adequately ‌test its Roundup weedkiller before selling it, starting a trial that could help determine the viabilit…

● Business WireSep 17, 2026 · 02:30 ET
Bayer's KERENDIA® (finerenone) Receives FDA Approval as the First New Treatment in 30 Years for Adults with Chronic Kidney Disease (CKD) and Type 1 Diabetes

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Summary Bayer today announced that the U.S. Food and Drug Administration (FDA) approved KERENDIA® (finerenone) to reduce urinary albumin-to-creatinine ratio (UACR), which is expecte…

● Business WireSep 10, 2026 · 15:54 ETCOMPANY'S OWN WORDS
Bayer Launches Nationwide Science Delivers Tour to Take Science on the Road

WHIPPANY, N.J.--(BUSINESS WIRE)--Amid growing concerns over misinformation around health and science, Bayer launched a nationwide tour of its Science Delivers mobile interactive experience. The mobile display hits the ro…

● Business WireSep 9, 2026 · 22:21 ET
U.S. FDA Grants Accelerated Approval to Bayer's HYRNUO® (sevabertinib) as a First-Line Targeted Therapy for Patients with HER2-Mutated Non-Small Cell Lung Cancer

WHIPPANY, N.J.--(BUSINESS WIRE)--U.S. FDA Grants Accelerated Approval to Bayer's HYRNUO® (sevabertinib) as a First-Line Targeted Therapy for Patients with HER2-Mutated NSCLC.…

No upcoming events in the feeds.

ANT13−7.0%
AAPL8+0.3%
FOX6−2.9%
META6−2.2%

Article counts from the last market-wide feed page, across every symbol we track and not just BAYRY · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.